Keywords: merck, co, pulls, billion/year, blockbuster, drug, vioxx
Merck & Co pulls $2.5 billion/year blockbuster drug Vioxx on safety fears
Article | 04 October 2004
In a move that depressed the US stock market and drug shares in particular on September 30, when drug major Merck & ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
